Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous cluster immunotherapy with grass pollen allergoid in allergic rhinitis
2010-022083-12Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jul 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of CLUSTOID Wiesenlieschgras in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Primary efficacy. Started Jul 2011; status: completed.
02
Drugs
CLUSTOID Wiesenlieschgras
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2010-022083-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022083-12.